Pfizer’s bid for AstraZeneca augurs monster M&A bond
The prospect of Pfizer sweetening its takeover bid for UK rival AstraZeneca to £64bn ($108bn) or more is raising expectations of a jumbo bond financing by the US pharmaceuticals major.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts